Aprotinin versus tranexamic acid: the controversy continues.
Publication
, Journal Article
Levy, JH
Published in: Transfusion
March 2006
Duke Scholars
Published In
Transfusion
DOI
ISSN
0041-1132
Publication Date
March 2006
Volume
46
Issue
3
Start / End Page
319 / 320
Location
United States
Related Subject Headings
- Tranexamic Acid
- Risk Factors
- Retrospective Studies
- Male
- Humans
- Hemostatics
- Fibrinolysis
- Female
- Drug-Related Side Effects and Adverse Reactions
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Levy, J. H. (2006). Aprotinin versus tranexamic acid: the controversy continues. Transfusion, 46(3), 319–320. https://doi.org/10.1111/j.1537-2995.2006.00767.x
Levy, Jerrold H. “Aprotinin versus tranexamic acid: the controversy continues.” Transfusion 46, no. 3 (March 2006): 319–20. https://doi.org/10.1111/j.1537-2995.2006.00767.x.
Levy JH. Aprotinin versus tranexamic acid: the controversy continues. Transfusion. 2006 Mar;46(3):319–20.
Levy, Jerrold H. “Aprotinin versus tranexamic acid: the controversy continues.” Transfusion, vol. 46, no. 3, Mar. 2006, pp. 319–20. Pubmed, doi:10.1111/j.1537-2995.2006.00767.x.
Levy JH. Aprotinin versus tranexamic acid: the controversy continues. Transfusion. 2006 Mar;46(3):319–320.
Published In
Transfusion
DOI
ISSN
0041-1132
Publication Date
March 2006
Volume
46
Issue
3
Start / End Page
319 / 320
Location
United States
Related Subject Headings
- Tranexamic Acid
- Risk Factors
- Retrospective Studies
- Male
- Humans
- Hemostatics
- Fibrinolysis
- Female
- Drug-Related Side Effects and Adverse Reactions
- Cardiovascular System & Hematology